BioCryst Pharmaceuticals BCRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $263.86M+397% | -$88.88M+60.8% | -$226.54M+8.3% | -$247.12M-34.3% | ||
| $1.39M+11.5% | $1.25M-24.7% | $1.66M+15.2% | $1.44M+84.9% | ||
| $85.07M+30.0% | $65.41M+17.6% | $55.62M+24.4% | $44.7M+29.0% | ||
| $347.37M— | —— | -$95.14M+41.2% | -$161.85M-13.9% | ||
| $2.47M+120% | $1.12M-48.2% | $2.17M+60.5% | $1.35M-43.4% | ||
| —— | —— | —— | —— | ||
| -$13.69M-125% | $55.04M— | —— | —— | ||
| —— | —— | $300M— | —— | ||
| -$349.93M— | —— | $35.66M-59.5% | $88.03M-75.5% | ||
| -$14.99M— | —— | -$198.49M— | —— | ||
| $344.9M— | —— | -$97.31M+40.4% | -$163.2M-12.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
